A new treatment for ALS, which uses a technique that turns off the mutated SOD1 gene, has passed an early phase clinical trial for safety.
By increasing the signaling activity of a protein called muscle skeletal receptor tyrosine-protein kinase (MuSK), researchers were able to keep nerve cells attached to muscle longer into the progression of the disease in a mouse model of ALS.
